与洛萨坦治疗相关的明显肝毒性:一个病例报告
Iman Zahedi1, Mohamed Sami2, Olumide Ijishakin3
1Internal Medicine, Arrowhead Regional Medical Center, San Bernardino, USA.
Cureus
|January 3, 2024
概括
这份案例报告强调了一种罕见的严重肝损伤病例,该病例是由洛萨坦 (losartan) 引起的,洛萨坦是治疗高血压的常见药物. 早期识别和停止洛萨坦治疗对于管理药物诱导的肝毒性至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
- 内部医学 内部医学
背景情况:
- 洛萨坦是一种血管激素II受体阻断剂 (ARB),经常用于高血压和心血管疾病.
- 虽然通常是安全的,但罕见的洛萨坦诱导肝毒性病例已被记录.
- 药物诱导性肝损伤 (DILI) 在药物管理中提出了重大临床挑战.
研究的目的:
- 报告与洛萨坦相关的严重肝损伤和亚 fulminant 肝炎病例.
- 强调考虑洛萨坦作为药物诱导肝毒性的潜在原因的重要性.
- 为有关与ARBs相关的药物不良反应的文献做出贡献.
主要方法:
- 一个54岁的男性高血压患者的案例研究.
- 用临床表现,实验室发现 (血清学) 和成像来诊断严重的肝损伤.
- 进行了差异诊断,以排除肝损伤的其他原因.
- 治疗包括停用洛萨坦,N-乙半氨酸和支持性护理.
主要成果:
- 患者表现出症状,包括腹痛,黄,深色尿液,吐和改变的感觉.
- 诊断工作证实严重的肝损伤,导致洛萨坦诱导的肝毒性诊断.
- 患者在停止服用洛沙坦并接受N-乙囊和支持性治疗后逐渐改善.
- 在康复期间,仔细监测肝酶水平.
结论:
- 洛萨坦应该被认为是严重药物诱导肝毒性的潜在原因.
- 及时识别和撤销侵权因素对于患者的康复至关重要.
- 这一案例强调了需要警监测服用洛沙坦的患者的肝功能,特别是那些有风险因素的患者.
更多相关视频
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
23.6K
06:38Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
Published on: March 11, 2016
12.1K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
433
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
433
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
735
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
735
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
569
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
569
01:25Antihypertensive Drugs: Direct Renin Inhibitors
632
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
632
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
645
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
645
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K